BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, Hou LJ, Ye ZH, Zhang XH, Zhao HC. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386. [PMID: 33744409 DOI: 10.1016/j.trim.2021.101386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
2 Aby ES, Lake JR. Immune Checkpoint Inhibitor Therapy Before Liver Transplantation—Case and Literature Review. Transplantation Direct 2022;8:e1304. [DOI: 10.1097/txd.0000000000001304] [Reference Citation Analysis]
3 Vogel A, Sterneck M, Vondran F, Waidmann O, Klein I, Lindig U, Nadalin S, Settmacher U, Tacke F, Schlitt HJ, Wege H. [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment]. Z Gastroenterol 2021. [PMID: 34670296 DOI: 10.1055/a-1649-8643] [Reference Citation Analysis]
4 Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:6307. [PMID: 34944927 DOI: 10.3390/cancers13246307] [Reference Citation Analysis]